Crispr moves ahead in GPC3
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Innovent takes the dual payload glory
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
More ROR1s enter the clinic
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Ivonescimab takes on pancreatic cancer
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
No holding back Claudin
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
